Patents Assigned to ONO
  • A METHOD FOR TREATING SWI/SNF COMPLEX-DEFICIENT CANCERS COMPRISING GLUTATHIONE (GSH) METABOLIC PATHWAY INHIBITOR
    Publication number: 20220087987
    Abstract: The present invention provides a method for treating SWI/SNF complex-deficient cancers comprising a glutathione (GSH) metabolic pathway inhibitor, a pharmaceutical composition comprising a glutathione (GSH) metabolic pathway inhibitor for therapy in SWI/SNF complex-deficient cancers, and a glutathione (GSH) metabolic pathway inhibitor for use in treating SWI/SNF complex-deficient cancers. The present invention also provides a method for detecting and/or selecting a susceptible patient to a glutathione (GSH) metabolic pathway inhibitor.
    Type: Application
    Filed: December 16, 2019
    Publication date: March 24, 2022
    Applicants: National Cancer Center, ONO PHARMACEUTICAL CO., LTD.
    Inventors: Hideaki OGIWARA, Takashi KOHNO, Hiroki SASAKI
  • BENZENE DERIVATIVE
    Publication number: 20220089532
    Abstract: A compound represented by general formula (I) (in the formula, all symbols are as described in the description) or a salt thereof has a potent nerve-protecting and/or -repairing activity, and therefore can be used as a therapeutic agent for neuropathy (e.g., chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, periarteritis nodosa, allergic vasculitis, diabetic peripheral neuropathy, entrapment neuropathy, peripheral neuropathy associated with the administration of a chemotherapeutic drug, or peripheral neuropathy associated with Charcot-Marie-Tooth disease).
    Type: Application
    Filed: December 7, 2021
    Publication date: March 24, 2022
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shoji NOJIMA, Kenji SASAKI, Tohru KAMBE, Takashi KONEMURA, Yoshikazu GOTO
  • Method for extracting sea cucumber saponin-containing extract and method for maintaining constant content thereof
    Patent number: 11272727
    Abstract: The method extracts an extract containing sea cucumber saponins. The extract is separated from sea cucumber meat exclusively by a specific heat treatment without conducting any chemical treatment with the use of an enzyme, ethanol, etc. The method includes: a step for heating sea cumbers from a starting temperature to a target heating temperature by a first temperature gradient; and a step for decreasing the temperature by a second temperature gradient that is gentler than the first temperature gradient to thereby extract the sea cucumber extract. The sea cucumber extract is stored as a sea cucumber extract material in the form of a liquid concentrate, etc. Then an appropriate amount of the sea cucumber extract material is added to, for example, another sea cucumber extract material having been separated and extracted from sea cucumbers with a lower saponin content.
    Type: Grant
    Filed: August 18, 2018
    Date of Patent: March 15, 2022
    Assignees: ISF LLC, IWATE PREFECTURE, IWATE MEDICAL UNIVERSITY, SANSHOU INC, ONO FOODS CO. LTD
    Inventors: Akira Yano, Mitsuo Kishi, Takao Sawai, Takao Sasaki, Akio Ono
  • Benzene derivative
    Patent number: 11261154
    Abstract: A compound represented by general formula (I) (in the formula, all symbols are as described in the description) or a salt thereof has a potent nerve-protecting and/or -repairing activity, and therefore can be used as a therapeutic agent for neuropathy (e.g., chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, periarteritis nodosa, allergic vasculitis, diabetic peripheral neuropathy, entrapment neuropathy, peripheral neuropathy associated with the administration of a chemotherapeutic drug, or peripheral neuropathy associated with Charcot-Marie-Tooth disease).
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: March 1, 2022
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shoji Nojima, Kenji Sasaki, Tohru Kambe, Takashi Konemura, Yoshikazu Goto
  • COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY
    Publication number: 20220055986
    Abstract: A compound represented by the general formula (V) wherein all the symbols are as defined in the specification, has an improved balance of the agonist activity against the S1P5 receptor relative to the S1P1 receptor, and can thus serve as a therapeutic agent for S1P5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases.
    Type: Application
    Filed: November 8, 2021
    Publication date: February 24, 2022
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Toshihide WATANABE, Kensuke KUSUMI, Satomi IMAIDE, Toshimitsu ENDO, Takaki KOMIYA, Naomi TSUBURAYA
  • TRICYCLIC SPIRO COMPOUND
    Publication number: 20220048881
    Abstract: A medicinal agent for the prevention and/or treatment of diseases caused by EP4 receptor activation is disclosed. A compound having antagonistic activity against the EP4 receptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EP4 receptor for the prevention and/or treatment of diseases caused by EP4 receptor activation.
    Type: Application
    Filed: October 29, 2021
    Publication date: February 17, 2022
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Masaki ASADA, Kousuke Tani, Masaya Hirobe, Satonori Higuchi, Kazuhiro Fuchibe, Ryo Oikawa, Tohru Kotani, Hirotsugu Takano
  • DP ANTAGONIST
    Publication number: 20220033371
    Abstract: An object of the present invention is to provide a DP receptor antagonist. A compound represented by general formula (I): (wherein all symbols are as shown in the specification) and a pharmaceutically acceptable salt thereof have DP receptor antagonistic activity and are also highly safe, and thus are useful as active ingredients of pharmaceuticals for DP receptor-mediated diseases. In addition, the compound represented by the general formula (I) and the pharmaceutically acceptable salt thereof also have good transferability to the central nervous system, and thus are particularly useful as a preventive and/or therapeutic agent for diseases associated with DP receptors present in the central nervous system among DP receptor-mediated diseases, that is, sleep-wake disorders.
    Type: Application
    Filed: September 19, 2019
    Publication date: February 3, 2022
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Masaki ASADA, Keisuke HANADA, Satonori HIGUCHI, Atsushi NAGANAWA, Yasuhiro TAKEDA
  • IMMUNOSUPPRESIVE AGENT
    Publication number: 20220025051
    Abstract: An immunosuppressive agent containing a substance that is selected from anti-CD80 antibodies and anti-PD-L1 antibodies and that promotes binding between PD-L1 and PD-1.
    Type: Application
    Filed: December 6, 2019
    Publication date: January 27, 2022
    Applicants: ONO PHARMACEUTICAL CO., LTD., TOKUSHIMA UNIVERSITY
    Inventors: Taku OKAZAKI, Daisuke SUGIURA, Takeo MAEDA, Shiro SHIBAYAMA
  • TREATMENT OF CANCER BY COMBINATION OF IMMUNE CHECKPOINT INHIBITOR AND FOLFIRINOX THERAPY
    Publication number: 20220008421
    Abstract: A new therapeutic method in which a combination of an immune checkpoint inhibitor and a FOLFIRINOX therapy, a modified FOLFIRINOX therapy or a dose-reducing regimen of each of the therapies is effective to treat cancer, particularly cancer difficult to treat with conventional therapies such as pancreatic cancer.
    Type: Application
    Filed: November 26, 2019
    Publication date: January 13, 2022
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Keisuke KIMURA, Masataka KURODA, Takeyuki IWATA
  • Biomarker for diagnosis of irritable bowel syndrome
    Patent number: 11215607
    Abstract: To provide a biomarker which is a metabolite included in a biological sample, and which can be collected in a noninvasive method and detected in a convenient analysis method, and which varies according to progression of pathological conditions of irritable bowel syndrome (IBS). Furthermore, such biomarkers are useful for determination of the presence or absence of morbidity of IBS, determination of severity of IBS, determination of types of IBS, determination of necessity of treatment of IBS, and confirmation of drug efficacy of an IBS therapeutic agent.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: January 4, 2022
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shin Fukudo, Seishi Katsumata, Hideaki Tada, Akio Hayashi, Chie Murata
  • NOVEL CRYSTAL OF (3S)-3-[2-(6-AMINO-2-FLUOROPYRIDIN-3-YL)-4-FLUORO-1H-IMIDAZOL-5-YL]-7-[5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL]-2,3-DIHYDROINDOLIZIN-5(1H)-ONE
    Publication number: 20210395250
    Abstract: A novel crystal form of (3S)-3-[2-(6-amino-2-fluoropyridin-3-yl)-4-fluoro-1H-imidazol-5-yl]-7-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]-2,3-dihydroindolizin-5(1H)-one, which is (3S)-3-[2-(6-amino-2-fluoropyridin-3-yl)-4-fluoro-1H-imidazol-5-yl]-7-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]-2,3-dihydroindolizin-5(1H)-one-3-hydroxybenzoic acid (1/1).
    Type: Application
    Filed: November 29, 2019
    Publication date: December 23, 2021
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Takayuki FUJITO, Shizuka ONO, Shuhei OHTANI
  • Compounds having S1P5 receptor agonistic activity
    Patent number: 11198672
    Abstract: A compound represented by the general formula (V) wherein all the symbols are as defined in the specification, has an improved balance of the agonist activity against the S1P5 receptor relative to the S1P1 receptor, and can thus serve as a therapeutic agent for S1P5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: December 14, 2021
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Toshihide Watanabe, Kensuke Kusumi, Satomi Imaide, Toshimitsu Endo, Takaki Komiya, Naomi Tsuburaya
  • Tricyclic spiro compound
    Patent number: 11192876
    Abstract: A medicinal agent for the prevention and/or treatment of diseases caused by EP4 receptor activation is disclosed. A compound having antagonistic activity against the EP4 receptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EP4 receptor for the prevention and/or treatment of diseases caused by EP4 receptor activation.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: December 7, 2021
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Masaki Asada, Kousuke Tani, Masaya Hirobe, Satonori Higuchi, Kazuhiro Fuchibe, Ryo Oikawa, Tohru Kotani, Hirotsugu Takano
  • NOVEL SALT OF 4-({(4S)-1-(4-CARBAMIMIDOYLBENZOYL)-4-[4(METHYLSULFONYL)PIPERAZIN-1-YL]-L-PROLYL}AMINO) BENZOIC ACID AND NOVEL CRYSTAL FORM THEREOF
    Publication number: 20210371379
    Abstract: 4-({(4S)-1-(4-Carbamimidoylbenzoyl)-4-[4-(methylsulfonyl)piperazin-1-yl]-L-prolyl}amino) benzoic acid di(4-toluenesulfonate) or dibenzenesulfonate or their crystal forms can be useful pharmaceutical ingredients because of their low hygroscopicity and excellent storage stability.
    Type: Application
    Filed: September 19, 2019
    Publication date: December 2, 2021
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Taihei NISHIYAMA, Takahiro NEKADO
  • STING AGONISTIC COMPOUND
    Publication number: 20210363166
    Abstract: A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1): wherein all symbols represent the same meanings as described in the specification, and the compound can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.
    Type: Application
    Filed: August 6, 2021
    Publication date: November 25, 2021
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Ryosuke HANADA, Masaya KOKUBO, Masakuni KURONO, Kenichi KOUDA, Hiroshi HAGIYA
  • ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS
    Publication number: 20210347773
    Abstract: Disclosed is a compound of formula (I): wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.
    Type: Application
    Filed: May 24, 2021
    Publication date: November 11, 2021
    Applicants: ONO PHARMACEUTICAL CO., LTD., VANDERBILT UNIVERSITY
    Inventors: Craig W. LINDSLEY, Joshua M. WIETING, Kevin M. MCGOWAN, Jerod S. DENTON, Kentaro YASHIRO, Haruto KURATA, Yoko SEKIOKA, Takahiro MORI, Yuzo IWAKI
  • BENZENE DERIVATIVE
    Publication number: 20210332009
    Abstract: A compound represented by general formula (I) (in the formula, all symbols are as described in the description) or a salt thereof has a potent nerve-protecting and/or -repairing activity, and therefore can be used as a therapeutic agent for neuropathy (e.g., chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, periarteritis nodosa, allergic vasculitis, diabetic peripheral neuropathy, entrapment neuropathy, peripheral neuropathy associated with the administration of a chemotherapeutic drug, or peripheral neuropathy associated with Charcot-Marie-Tooth disease).
    Type: Application
    Filed: July 30, 2019
    Publication date: October 28, 2021
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shoji NOJIMA, Kenji SASAKI, Tohru KAMBE, Takashi KONEMURA, Yoshikazu GOTO
  • BISPECIFIC ANTIBODY
    Publication number: 20210332134
    Abstract: A bispecific antibody which is capable of specifically binding to PD-1 and CD3 is disclosed. The bispecific antibody is suitable for preventing, suppressing symptom progression or recurrence of, and/or treating autoimmune diseases. Also disclosed is a formulation which can reduce occurrence of adverse infusion reactions or adverse reaction called cytokine release syndrome. The bispecific antibody has the feature to allow interaction between PD-1 and PD-L1 as its ligand, contributes enhancement or duration of its effects.
    Type: Application
    Filed: July 2, 2021
    Publication date: October 28, 2021
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shiro SHIBAYAMA, Takuya SHIMBO, Tomoya TEZUKA, Mark THROSBY, Cornelis Adriaan de KRUIF, Pieter Fokko van LOO, Rinse KLOOSTER
  • STING agonistic compound
    Patent number: 11130773
    Abstract: A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1): wherein all symbols represent the same meanings as described in the specification, and the compound can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: September 28, 2021
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Ryosuke Hanada, Masaya Kokubo, Masakuni Kurono, Kenichi Kouda, Hiroshi Hagiya
  • STING AGONISTIC COMPOUND
    Publication number: 20210253615
    Abstract: A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1): wherein all symbols represent the same meanings as described in the specification, and the compound can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.
    Type: Application
    Filed: October 10, 2019
    Publication date: August 19, 2021
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Ryosuke HANADA, Masaya KOKUBO, Masakuni KURONO, Kenichi KOUDA, Hiroshi HAGIYA